07:22 AM EDT, 06/26/2025 (MT Newswires) -- I-Mab ( IMAB ) said Thursday that initial data from a phase 1b dose escalation study showed that givastomig with immunochemotherapy for metastatic gastric cancer achieved rapid responses that deepened over time in tumors with low PD-L1 and/or low Claudin 18.2 expression.

The company said objective response rates of 71% and 83% were observed across all dose levels and at dose levels selected for the dose expansion study, respectively, in patients who received givastomig combined with nivolumab and mFOLFOX6 chemotherapy.

I-Mab ( IMAB ) also said it observed a favorable safety profile with low incidence of gastrointestinal and liver toxicities.

I-Mab's ( IMAB ) shares were up more than 1% in recent premarket activity.